EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Ritonavir: 25 Years’ Experience of Concomitant Medication Management. A Narrative Review

Romina Quercia, Giovanni Di Perri, Carolina Pein, Jennifer Bodie, Ravi Shankar P Singh, Victoria Hendrick, Marta Boffito

Infectious Diseases and Therapy · 2024-05 · 13 (5) · 1005-1017

DOI: 10.1007/s40121-024-00959-6 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Infectious Diseases and Therapy, online erschienen am 12.04.2024. Verfasst von Romina Quercia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chief Medical Affairs Office, Pfizer Inc, New York City, NY, USA. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ritonavir is a potent inhibitor of the cytochrome P450 3A4 enzyme and is commonly used as a pharmacokinetic (PK) enhancer in antiviral therapies because it increases bioavailability of concomitantly administered antivirals. Decades of experience with ritonavir-enhanced HIV therapies and, more recently, COVID-19 therapies demonstrate that boosting doses of ritonavir are well tolerated, with an established safety profile. The mechanisms of PK enhancement by ritonavir result in the potential for drug-drug interactions (DDIs) with several classes of drugs, thus making co-medication management an important consideration with enhanced antiviral therapies. However, rates of DDIs with contraindicated medications are low, suggesting these risks are manageable by infectious disease specialists who have experience with the use of PK enhancers. In this review, we provide an overview of ritonavir's mechanisms of action and describe approaches and resources available to mitigate adverse events and manage concomitant medication in both chronic and short-term settings.

Schlagwörter

Stichwörter der Autor:innen

COVID-19Concomitant medication managementDrug–drug interactionsHIVNirmatrelvirRitonavir

Autor:innen und Institutionen

  • Chief Medical Affairs Office, Pfizer Inc, New York City, NY, USA.
  • Amedeo di Savoia Hospital, Turin, Italy.
  • Chief Medical Affairs Office, Pfizer Inc, New York City, NY, USA. mariacarolina.pein@pfizer.com.
  • Pfizer Research and Development, Pfizer Inc, Cambridge, MA, USA.
  • Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
  • Department of Infectious Diseases, Imperial College London, London, UK.

Förderung

  • Pfizer

Zitieren

APA

Quercia, R., Di Perri, G., Pein, C., Bodie, J., Singh, R. S. P., Hendrick, V., & Boffito, M. (2024). Ritonavir: 25 Years’ Experience of Concomitant Medication Management. A Narrative Review. Infectious Diseases and Therapy, 13(5), 1005-1017. https://doi.org/10.1007/s40121-024-00959-6

Vancouver

Quercia R, Di Perri G, Pein C, Bodie J, Singh RSP, Hendrick V, et al. Ritonavir: 25 Years’ Experience of Concomitant Medication Management. A Narrative Review. Infectious Diseases and Therapy. 2024;13(5):1005-1017. doi:10.1007/s40121-024-00959-6

BibTeX
@article{Quercia2024,
  author = {Quercia, Romina and Di Perri, Giovanni and Pein, Carolina and Bodie, Jennifer and Singh, Ravi Shankar P and Hendrick, Victoria and Boffito, Marta},
  title = {Ritonavir: 25 Years’ Experience of Concomitant Medication Management. A Narrative Review},
  journal = {Infectious Diseases and Therapy},
  year = {2024},
  volume = {13},
  number = {5},
  pages = {1005--1017},
  doi = {10.1007/s40121-024-00959-6}
}
Kostenlos starten →